Clinical trials: Carfilzomib
Non-Secretory Plasma Cell Myeloma, Plasmacytosis
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma
This phase I/Ib trial studies the side effects and best dose of panobinostat and carfilzomib in treating participants with multiple myeloma that has come back or that isn't responding to treatment.
- Conditions
- Non-Secretory Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01301807
- Testing
- Carfilzomib, Panobinostat
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma
Open-label phase Ib/II, multicenter, international non-comparative trial. This study is designed to determine the safety and efficacy of the novel salvage regimen (CBd) followed by a carfilzomib maintenance in patients with…
- Trial name
- NCT02056756
- Testing
- Carfilzomib
- Where
- 3 sites in Germany, Italy
- Volunteers
- 63 people
- Sponsor
- Stichting European Myeloma Network
Multiple Myeloma
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
The purpose of this study is to test any good and bad effects of giving a combination of study drugs before and after autologous stem cell transplant.
- Trial name
- NCT03556332
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Waldenstrom Macroglobulinemia
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
In Waldenström macroglobulinemia (WM) chemotherapy induces only low CR/VGPR (Complete Remission/ Very Good Partial Response) rates and responses of short duration compared to other indolent lymphomas.
- Trial name
- CZAR-1 (NCT04263480)
- Testing
- Carfilzomib + Ibrutinib, Ibrutinib
- Where
- 17 sites in Austria, Germany and 1 more
- Volunteers
- 99 people
- Sponsor
- Christian Buske
Highly Sensitized Prospective Kidney Transplant Recipients
Carfilzomib and Belatacept for Desensitization
Some kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors.
- Trial name
- ADAPT (NCT05017545)
- Testing
- carfilzomib, belatacept, Bone marrow aspiration
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Myeloma
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the standard of care…
- Trial name
- ADVANCE (NCT04268498)
- Testing
- Bortezomib, Dexamethasone, Lenalidomide
- Where
- 7 sites in United States
- Volunteers
- 310 people
- Sponsor
- University of Miami
Multiple Myeloma
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
This study is for adults with multiple myeloma (a type of blood cancer) that has come back after being treated earlier or isn't responding to the current treatment.
- Trial name
- NCT07227311
- Testing
- Belantamab mafodotin, Dexamethasone, Pomalidomide
- Where
- 59 sites in United States, France and 6 more
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
This phase II trial studies the effect of selinexor when combined with carfilzomib, daratumumab, and dexamethasone in treating patients with high-risk multiple myeloma that has come back (recurrent) or has not responded to…
- Trial name
- NCT04756401
- Testing
- Carfilzomib, Daratumumab, Dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Academic and Community Cancer Research United
Multiple Myeloma
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
- Trial name
- NCT03989414
- Testing
- CC-92480, Bortezomib, Dexamethasone
- Where
- 49 sites in United States, Canada and 7 more
- Volunteers
- 424 people
- Sponsor
- Celgene
Relapsed/Refractory Multiple Myeloma
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal…
- Trial name
- NCT04973605
- Testing
- Sonrotoclax, Dexamethasone, Carfilzomib
- Where
- 74 sites in United States, Australia and 11 more
- Volunteers
- 246 people
- Sponsor
- BeOne Medicines
Plasma Cell Myeloma
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
This phase II trial studies how well carfilzomib, pomalidomide, and dexamethasone work in treating patients with high-risk multiple myeloma.
- Trial name
- NCT03756896
- Testing
- Carfilzomib, Dexamethasone, Pomalidomide
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Emory University
Colorectal Neoplasms, Neoplasms
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Background: Cancers that begin in the colon, adrenal glands, or bile ducts may spread to the liver. These liver tumors are often treated using a hepatic artery infusion (HAI) pump.
- Conditions
- Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma
- Trial name
- NCT07715903
- Testing
- Carfilzomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Peripheral T Cell Lymphoma
Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
This is a multicentre phase I/II trial looking at the combination of romidepsin and carfilzomib. The aim of the phase I part is to determine the maximum tolerated dose (MTD) of the combination.
- Trial name
- RomiCar (NCT03141203)
- Testing
- Romidepsin, Carfilzomib
- Where
- 13 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Birmingham
Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
The purpose of this study is to test the safety and tolerability of carfilzomib at different dose levels on hematological cancers such as multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, or Waldenstrom's…
- Conditions
- Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
- Trial name
- NCT00150462
- Testing
- Carfilzomib, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Amgen
Newly Diagnosed Multiple Myeloma
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III trials in MM patients.
- Trial name
- NCT03948035
- Testing
- Elotuzumab, Carfilzomib, Lenalidomide
- Where
- 56 sites in Austria, Germany
- Volunteers
- 576 people
- Sponsor
- Wuerzburg University Hospital
Multiple Myeloma
Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients
The purpose of this study is to determine whether the association of Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) as induction treatment is safe and provides benefits in patients with newly diagnosed Multiple Myeloma…
- Trial name
- CCD (NCT01346787)
- Testing
- CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
- Where
- 13 sites in Italy, Netherlands
- Volunteers
- 58 people
- Sponsor
- European Myeloma Network B.V.
Multiple Myeloma
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
This study will evaluate the feasibility of combining four of the most active agents available for the treatment of multiple myeloma. Further the investigators will attempt to assess the activity of this combination.
- Trial name
- QUAD (NCT01297764)
- Testing
- Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Hackensack Meridian Health
Multiple Myeloma
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
The main aims of this study are to test for any side effects from modakafusp alfa in combination therapy and to determine the recommended dose of combination therapy with modakafusp alfa.
- Trial name
- iinnovate-2 (NCT05556616)
- Testing
- Modakafusp alfa, Lenalidomide, Bortezomib
- Where
- 21 sites in United States, Belgium and 2 more
- Volunteers
- 15 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
AML, ALL
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
This is a multicenter, open-label, dose escalation Phase 1 study.
- Conditions
- AML, ALL, Blast Crisis, MDS
- Trial name
- TG02-101 (NCT01204164)
- Testing
- TG02 citrate, Carfilzomib, Dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Tragara Pharmaceuticals, Inc.
Multiple Myeloma
A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
The study had the following primary objectives: Phase 1: to determine the maximum tolerated dose (MTD) of once-weekly (QW) carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma who have received…
- Trial name
- CHAMPION 1 (NCT01677858)
- Testing
- Carfilzomib, Dexamethasone
- Where
- 35 sites in United States
- Volunteers
- 116 people
- Sponsor
- Amgen